23 Jan Autolus Therapeutics
Posted at 17:13h
in
Christopher Vann, Ph.D., Chief Operating Officer
April 10 | 4:00pm | Salone dei Cavalieri, Section 3&4
London, United Kingdom
(NASDAQ GS: AUTL)
Autolus is a CAR T cell therapy company. We are applying our extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing benefits to cancer patients. Autolus is a leader in T cell programming, underpinning the broad technology toolbox and manufacturing technology. Autolus is developing cancer therapies which we believe will offer patients substantial benefits over the existing standard of care.
